Titan Biotech (BOM:524717) Debt-to-Equity : N/A (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Titan Biotech Debt-to-Equity?

Titan Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Titan Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0 Mil. Titan Biotech's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₹0 Mil.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Titan Biotech's Debt-to-Equity or its related term are showing as below:

BOM:524717' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.36 Max: 1.06
Current: 0.07

During the past 13 years, the highest Debt-to-Equity Ratio of Titan Biotech was 1.06. The lowest was 0.05. And the median was 0.36.

BOM:524717's Debt-to-Equity is ranked better than
66.42% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs BOM:524717: 0.07

Titan Biotech Debt-to-Equity Historical Data

The historical data trend for Titan Biotech's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Biotech Debt-to-Equity Chart

Titan Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

Get a 7-Day Free Trial

0.74

0.61

0.22

0.21

0.08

Titan Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															N/A	0.08	N/A	0.07	N/A

Competitive Comparison of Titan Biotech's Debt-to-Equity

For the Biotechnology subindustry, Titan Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Titan Biotech's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Titan Biotech's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Titan Biotech's Debt-to-Equity falls into.

Titan Biotech Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Titan Biotech's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(70.806	+	14.311)	/	1099.109
	=	0.08

Titan Biotech's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	0
	=	N/A

Titan Biotech (BOM:524717) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Titan Biotech Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Titan Biotech's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Biotech (BOM:524717) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Biotech Ltd (BOM:524717) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi, IND, 110034

Website

https://www.titanbiotechltd.com

Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The Company's business activity falls within a single primary business segment which is business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.

Titan Biotech (BOM:524717) Headlines

No Headlines